Nearly all of the clinical trial data in new drug marketing applications that are submitted to the European Medicines Agency for evaluation after 1 January 2015 will be made available to the public following the drug's approval, the agency's eagerly-awaited final policy on proactive publication of trial data has revealed1-3.
Information that will not be made available under the policy is that which is deemed to be commercially confidential or which affects patient confidentiality.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?